---
title: "Oragenics, Inc. (OGEN.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/OGEN.US.md"
symbol: "OGEN.US"
name: "Oragenics, Inc."
industry: "Biotechnology"
datetime: "2026-05-20T05:50:42.911Z"
locales:
  - [en](https://longbridge.com/en/quote/OGEN.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/OGEN.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/OGEN.US.md)
---

# Oragenics, Inc. (OGEN.US)

## Company Overview

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical therapies neurological conditions and infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid, which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification for the treatment of mild traumatic brain injury. The company was formerly known as Oragen, Inc. Oragenics, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.oragenics.com](https://www.oragenics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.25 | 97 | - | - | - |
| PB | 0.40 | 29 | 8.49 | 0.38 | 0.33 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-29T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.57 |
| Highest Target | 2.00 |
| Lowest Target | 2.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/OGEN.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/OGEN.US/norm.md)
- [Related News](https://longbridge.com/en/quote/OGEN.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/OGEN.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**